{"transactions":[{"id":693921,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-06T21:17:47.000Z","date":"2026-08-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall fully vest on the earlier of (i) August 4, 2027 and (ii) the next annual meeting of the Company's stockholders, subject to continued service to the Issuer through such date."}],"balance_after":27000,"derivative":{"exercise_price":17,"expiration_date":"2036-08-03","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-338446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000119312526338446/ownership.xml","form_type":"4"}},{"id":945647,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:49:07.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026."}],"balance_after":40000,"derivative":{"exercise_price":8.17,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001647664-26-000002","document":"form4-01062026_090103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000164766426000002/form4-01062026_090103.xml","form_type":"4"}},{"id":1103432,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T00:05:17.000Z","date":"2025-06-23","kind":"purchase","planned":false,"acquired":true,"shares":1403,"price":9.43,"value":13230.29,"ownership":{"direct":true},"balance_after":28000,"source":{"system":"sec-edgar","filing":"0001415889-25-018014","document":"form4-06242025_120613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000141588925018014/form4-06242025_120613.xml","form_type":"4"}},{"id":1103431,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T00:05:17.000Z","date":"2025-06-20","kind":"purchase","planned":false,"acquired":true,"shares":26597,"price":9.3871,"value":249668.6987,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 26,597 shares purchased in the price range of $9.14 to $9.50 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":26597,"source":{"system":"sec-edgar","filing":"0001415889-25-018014","document":"form4-06242025_120613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000141588925018014/form4-06242025_120613.xml","form_type":"4"}},{"id":1309683,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T21:47:57.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025."}],"balance_after":35000,"derivative":{"exercise_price":8.26,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-000795","document":"form4-01062025_090153.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000141588925000795/form4-01062025_090153.xml","form_type":"4"}},{"id":1478453,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:26:51.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":25600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":25600,"derivative":{"exercise_price":7.9,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":25600},"source":{"system":"sec-edgar","filing":"0001415889-24-016916","document":"form4-06142024_080646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000141588924016916/form4-06142024_080646.xml","form_type":"4"}},{"id":1614528,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-27T22:10:22.000Z","date":"2024-02-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40848,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.24,"expiration_date":"2032-11-30","underlying":"Common Stock","underlying_shares":40848},"source":{"system":"sec-edgar","filing":"0001415889-24-005545","document":"form4-02272024_100213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000141588924005545/form4-02272024_100213.xml","form_type":"4"}},{"id":1614527,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-27T22:10:22.000Z","date":"2024-02-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73731,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.24,"expiration_date":"2032-03-21","underlying":"Common Stock","underlying_shares":73731},"source":{"system":"sec-edgar","filing":"0001415889-24-005545","document":"form4-02272024_100213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000141588924005545/form4-02272024_100213.xml","form_type":"4"}},{"id":1853786,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T20:58:00.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":20500,"derivative":{"exercise_price":6.33,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-23-037398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000120919123037398/doc4.xml","form_type":"4"}},{"id":2226579,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-18T00:25:30.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":45158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(A) 11,958 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B)  one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022."}],"balance_after":45158,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":45158},"source":{"system":"sec-edgar","filing":"0001209191-22-038203","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000120919122038203/doc4.xml","form_type":"4"}},{"id":2517202,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-10T22:53:36.000Z","date":"2021-11-09","kind":"grant","acquired":true,"shares":33250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36th) of the shares subject to the option shall vest on each monthly anniversary of November 9, 2021."}],"balance_after":33250,"derivative":{"exercise_price":17.42,"expiration_date":"2031-11-08","underlying":"Common Stock","underlying_shares":33250},"source":{"system":"sec-edgar","filing":"0001209191-21-063926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647664/000120919121063926/doc4.xml","form_type":"4"}},{"id":4007995,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Bus. & Strat. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-07T17:57:32.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":180360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":180360,"derivative":{"exercise_price":2.36,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":180360},"source":{"system":"sec-edgar","filing":"0001209191-18-017785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919118017785/doc4.xml","form_type":"4"}},{"id":4392478,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Bus. & Strat. Officer"}}],"security":"Common Stock","published_at":"2017-03-09T18:01:12.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":30000,"price":1.43,"value":42900.0,"ownership":{"direct":true},"balance_after":133252,"source":{"system":"sec-edgar","filing":"0001209191-17-019696","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919117019696/doc4.xml","form_type":"4"}},{"id":4394610,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Bus. & Strat. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-03-08T17:44:19.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on January 1, 2018, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.45,"expiration_date":"2027-03-06","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-17-019361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919117019361/doc4.xml","form_type":"4"}},{"id":4586526,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":25740,"kind":"person","name":"You Angie","position":1,"cik":"0001647664","reported_name":"You Angie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Bus. & Strat. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2016-10-04T17:07:24.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.7778% of the total shares monthly, beginning on October 30, 2016, with 100% of the total shares vested and exercisable on September 30, 2019, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":1.82,"expiration_date":"2026-09-30","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-16-144423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919116144423/doc4.xml","form_type":"4"}}]}